Injection needle coating material and its use in surface treatment of peripheral blood collection needle

Abstract

The present invention discloses a coating material for an injection needle and its use in the surface treatment of a peripheral blood collection needle, and relates to the field of biomedical materials technology. The coating material for an injection needle is formed by dipping the injection needle into a coating solution to form a coating on the needle surface; wherein the raw material composition of the coating solution includes, by weight, 1 to 4 parts by weight of modified silicone oil, 20 to 30 parts of 4-chlorotrifluorotoluene, 15 to 30 parts of ethyl acetate, 2 to 4 parts of hydroxypropyl methylcellulose, 3 to 8 parts of dimethylformamide, 0.5 to 2 parts of fucoidan sulfate, and 0.1 to 1 part of luteolin-5-O-glucoside. The coating material prepared by the present invention has good adhesion, is not easy to fall off when applied to the needle surface, and can greatly reduce the pain of the patient during puncture; has excellent anticoagulant effect, and can alleviate the problem that the patient's blood coagulation is fast and is not conducive to subsequent testing.

Description

Technical Field

[0001] The invention belongs to the technical field of biomedical materials, and in particular relates to an injection needle coating material and application thereof in surface treatment of a peripheral blood collection needle. Background Art

[0002] A peripheral lancet is a commonly used medical device that uses the tip of the lancet to pierce the patient's skin to collect a blood sample. There are many types of lancet structures currently on the market, and most of them are trigger-type ejection structures. In the existing technology, injection needles are mostly disposable stainless steel needles. During the injection, the friction between the needle surface and the skin and flesh tissue is relatively large, so the pain is relatively strong. It is very necessary to study how to reduce the pain of injection or blood collection. In addition, during the blood collection process in the hospital, some patients release thrombin faster, causing the collected blood to coagulate faster in the test tube, which will cause unnecessary effects on subsequent laboratory tests and other processes. Sometimes medical staff will add anticoagulants to the collected blood again, but the process of adding anticoagulants is complicated. Therefore, there is a need for a lancet that can prevent blood coagulation during the blood collection process. Summary of the Invention

[0003] The purpose of the present invention is to provide an injection needle coating material and its use in the surface treatment of peripheral blood collection needles. The coating material has good adhesion, is not easy to fall off when coated on the needle surface, and can greatly reduce the pain of the patient during puncture; it has excellent anticoagulant effect, which can alleviate the problem of rapid blood coagulation of patients, which is not conducive to subsequent testing.

[0004] The technical solutions adopted by the present invention to achieve the above-mentioned purpose are:

[0005] This invention discloses the use of a caffeic acid-lupeol-modified silicone oil in the preparation of a coating material for injection needles. When applied to the surface of an injection needle, the silicone oil coating can increase the lubricity of the needle tip and reduce stinging sensation. When applied to the needle tip, the coating material, prepared using the caffeic acid-lupeol-modified silicone oil, effectively reduces puncture force and significantly reduces stinging sensation. The presence of caffeic acid-lupeol also effectively enhances the coating material's adhesion to the needle tip surface, preventing it from falling off and improving the material's anti-icing properties.

[0006] Preferably, the preparation method of the modified silicone oil is specifically as follows:

[0007] Caffeic acid lupeol and polymethylhydrogen siloxane are dissolved in DMSO, and the temperature is raised to 80-90°C under nitrogen protection. 3-6 ppm of Speier catalyst is added and the reaction is carried out for 4-6 hours. The modified silicone oil is filtered while hot, cooled to room temperature, rotary evaporated, dried, and then separated and purified by column chromatography.

[0008] Preferably, the mass ratio of caffeic acid lupeol to polymethylhydrogensiloxane is 3 to 5:1.

[0009] Furthermore, caffeic acid and lupeol are used to enhance the lubricity and anti-icing properties of silicone oil.

[0010] A coating material for an injection needle is formed by impregnating the needle tip with a coating solution containing the above-mentioned modified silicone oil to form a coating on the needle tip surface. The modified silicone oil coating made by the formula of the present invention can greatly increase the lubricity of the needle tip and greatly reduce the pain of piercing the patient's body; and the functional groups in the structure of the caffeic acid lupeol modified silicone oil, compounded with other components, can effectively improve the adhesion of the material through high-activity cross-linking technology. At the same time, the presence of caffeic acid lupeol significantly enhances the anti-icing performance of the coating material surface, improves the coating performance, and effectively prevents the needle tip surface from freezing under low temperature conditions. When the needle tip coated with the coating of the present invention is used for injection, the friction with the skin and flesh tissue can be greatly reduced, thereby greatly reducing the pain. The patient can hardly feel the tingling sensation caused by the needle tip inserting into the skin tissue. In addition, it has high adhesion to the stainless steel needle tip and is not easy to fall off, which has the value of promotion and application.

[0011] Preferably, the needle tip of the injection needle is immersed in the coating solution and then heated and dried at a temperature of less than 150°C.

[0012] Preferably, the coating solution comprises, by weight, 1 to 4 parts of modified silicone oil, 20 to 30 parts of 4-chlorotrifluorotoluene, 15 to 30 parts of ethyl acetate, 2 to 4 parts of hydroxypropyl methylcellulose, and 3 to 8 parts of dimethylformamide.

[0013] Furthermore, the raw material components of the coating solution also include 0.5 to 2 parts by weight of fucoidan sulfate, and / or 0.1 to 1 parts by weight of luteolin-5-O-glucoside. The presence of fucoidan sulfate gives the coating material a certain anticoagulant effect; the modified silicone oil and its synergistic effect have a certain enhancement effect on the anticoagulant effect of the coating material; the presence of luteolin-5-O-glucoside, when used in combination with fucoidan sulfate, can significantly enhance the anticoagulant effect of the coating material. After being used for the surface treatment of peripheral blood collection needles, it can alleviate the problem of rapid blood coagulation of patients, which is not conducive to subsequent testing, to a certain extent. In addition, the combination of luteolin-5-O-glucoside and modified silicone oil can significantly improve the adhesion of the coating material on the needle surface and enhance the bonding force.

[0014] The invention also discloses the application of the coating material in the surface treatment of a peripheral blood collection needle.

[0015] Preferably, the coating thickness is 10 to 30 μm.

[0016] Compared with the prior art, the present invention has the following beneficial effects:

[0017] The modified silicone oil coating formulated with the present invention's formula can significantly increase the lubricity of needles, significantly reducing the pain of puncturing a patient. Furthermore, the caffeic acid lupeol-modified silicone oil, when combined with other components, effectively enhances the material's adhesion, improving adhesion to stainless steel needles and preventing them from falling off, making it valuable for widespread application. Furthermore, the presence of caffeic acid lupeol significantly enhances the coating's surface anti-icing properties, improving coating performance and effectively preventing ice from forming on the needle surface under low-temperature conditions. Furthermore, the presence of fucoidan sulfate imparts a certain anticoagulant effect to the coating. The addition of luteolin-5-O-glucoside synergistically enhances the coating's anticoagulant effect. When used to treat the surface of peripheral blood collection needles, it can alleviate the problem of rapid blood clotting in patients, which can hinder subsequent testing. Furthermore, the combination of luteolin-5-O-glucoside with the modified silicone oil further enhances the coating's adhesion to the needle surface, improving its performance.

[0018] Therefore, the present invention provides an injection needle coating material and its use in the surface treatment of peripheral blood collection needles. The coating material has good adhesion, is coated on the needle surface, is not easy to fall off, and can greatly reduce the pain of the patient during puncture; it has excellent anticoagulant effect, which can alleviate the problem of rapid blood coagulation of patients, which is not conducive to subsequent testing. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 This is the infrared test result of Test Example 1 of the present invention. DETAILED DESCRIPTION

[0020] The technical solution of the present invention is further described in detail below with reference to the specific embodiments and the accompanying drawings:

[0021] The polymethylhydrogensiloxane used in the examples of the present invention was purchased from Shanghai MacLean Biochemical Technology Co., Ltd.

[0022] Example 1:

[0023] Preparation of modified silicone oil:

[0024] Caffeic acid lupeol and polymethylhydrogen siloxane (the mass ratio of caffeic acid lupeol to polymethylhydrogen siloxane is 4.2:1) were dissolved in DMSO, and the temperature was raised to 85°C under nitrogen protection. 5 ppm of Speier catalyst was added and the reaction was carried out for 5 hours. The mixture was filtered while hot, cooled to room temperature, rotary evaporated, dried, and then separated and purified by column chromatography to obtain modified silicone oil.

[0025] The raw material components of a coating solution for an injection needle coating material include: by weight, 3.5 parts of modified silicone oil, 28 parts of 4-chlorotrifluorotoluene, 25 parts of ethyl acetate, 3 parts of hydroxypropyl methylcellulose, and 6 parts of dimethylformamide.

[0026] A coating material for an injection needle is formed on the surface of the needle tip by dipping the needle tip into a coating solution, with a coating thickness of 15±0.7 μm.

[0027] Example 2:

[0028] The preparation of modified silicone oil is the same as that of Example 1;

[0029] The raw material components of a coating solution for an injection needle coating material include: by weight, 3.5 parts of modified silicone oil, 28 parts of 4-chlorotrifluorotoluene, 25 parts of ethyl acetate, 3 parts of hydroxypropyl methylcellulose, 6 parts of dimethylformamide, and 1.2 parts of fucoidan sulfate.

[0030] The preparation of an injection needle coating material is the same as that in Example 1, and the coating thickness is 24.5±0.3 μm.

[0031] Example 3:

[0032] The preparation of the modified silicone oil differs from that of Example 2 in that the mass ratio of caffeic acid lupeol to polymethylhydrogensiloxane is 3.8:1;

[0033] The raw material components of a coating solution for an injection needle coating material include: by weight, 2 parts of modified silicone oil, 22 parts of 4-chlorotrifluorotoluene, 16 parts of ethyl acetate, 2 parts of hydroxypropyl methylcellulose, 5 parts of dimethylformamide, and 0.9 part of fucoidan sulfate.

[0034] The preparation of an injection needle coating material is the same as that in Example 1, and the coating thickness is 14.3±0.5 μm.

[0035] Example 4:

[0036] The preparation of the modified silicone oil differs from that of Example 1 in that the mass ratio of caffeic acid lupeol to polymethylhydrogensiloxane is 3.2:1;

[0037] The raw material components of a coating solution for an injection needle coating material include: by weight, 4 parts of modified silicone oil, 30 parts of 4-chlorotrifluorotoluene, 28 parts of ethyl acetate, 4 parts of hydroxypropyl methylcellulose, 8 parts of dimethylformamide, and 1.8 parts of fucoidan sulfate.

[0038] The preparation of an injection needle coating material is the same as that in Example 1, and the coating thickness is 28.6±0.6 μm.

[0039] Example 5:

[0040] The preparation of modified silicone oil is the same as in Example 1;

[0041] The raw material components of a coating solution for an injection needle coating material include: by weight, 3.5 parts of modified silicone oil, 28 parts of 4-chlorotrifluorotoluene, 25 parts of ethyl acetate, 3 parts of hydroxypropyl methylcellulose, 6 parts of dimethylformamide, and 0.6 parts of luteolin-5-O-glucoside.

[0042] The preparation of an injection needle coating material is the same as that in Example 1, and the coating thickness is 16.1±0.8 μm.

[0043] Example 6:

[0044] The preparation of modified silicone oil is the same as in Example 2;

[0045] The raw material components of a coating solution for an injection needle coating material include, by weight, 3.5 parts of modified silicone oil, 28 parts of 4-chlorotrifluorotoluene, 25 parts of ethyl acetate, 3 parts of hydroxypropyl methylcellulose, 6 parts of dimethylformamide, 1.2 parts of fucoidan sulfate, and 0.6 parts of luteolin-5-O-glucoside.

[0046] The preparation of an injection needle coating material is the same as that in Example 1, and the coating thickness is 26.5±0.8 μm.

[0047] Comparative Example 1:

[0048] The difference between a coating solution for an injection needle coating material and Example 1 is that silicone oil is used instead of modified silicone oil.

[0049] The preparation of an injection needle coating material is the same as that in Example 1, and the coating thickness is 17.7±0.6 μm.

[0050] Comparative Example 2:

[0051] The difference between a coating solution for an injection needle coating material and Example 2 is that silicone oil is used instead of modified silicone oil.

[0052] The preparation of an injection needle coating material is the same as that in Example 1, and the coating thickness is 21.7±0.4 μm.

[0053] Test Example 1:

[0054] 1. Infrared spectroscopy (FT-IR)

[0055] After the sample was dehydrated in a constant temperature drying oven, a small amount of the sample was mixed with potassium bromide in an agate mortar, ground, and pressed into a pellet. The pellet was then tested on a TENSOR 27 infrared spectrometer with a scanning wavenumber range of 4000–500 cm -1 , scanning resolution is 6cm -1 , the number of scans is 18.

[0056] The above test was carried out on polymethyl hydrogen siloxane and the modified polymethyl hydrogen siloxane prepared in Example 1. The results are as follows: Figure 1 As shown in the figure, compared with the infrared spectrum of polymethylhydrogensiloxane, the infrared absorption of the modified -1 The characteristic absorption peak of methylene appears near 2110cm -1 The Si-H absorption peak near 1749 cm -1 The characteristic absorption peak of C=O in the ester group appears near 1700cm -1 The C=C characteristic absorption peak appears near 1500~1650cm -1 The characteristic absorption peak of benzene ring appears in the range of 750cm -1 The above results indicate that the modified polymethylhydrogensiloxane was successfully prepared.

[0057] 2. Adhesion test of coating after immersion in water

[0058] Apply the sample coating to a stainless steel substrate, dry it, and soak it in a constant-temperature water bath controlled at 37°C ± 0.5°C. After a certain period of time, remove the sample from the water bath and quickly dry the surface with filter paper. Immediately scratch the coating with a special scraper. Attach adhesive tape to the scratch and roll the tape back and forth three times with a 5kg roller to ensure a close bond between the tape and the coating. Then quickly peel the tape off. Record the soaking time the coating undergoes before peeling, which is the adhesion failure time.

[0059] The above test was performed on the coating materials obtained in Comparative Examples 1 to 2 and Examples 1 to 6. The results are shown in Table 1:

[0060] Table 1 Adhesion test results

[0061] sample Adhesion failure time / h Comparative Example 1 48 Comparative Example 2 52 Example 1 74 Example 2 69 Example 3 71 Example 4 68 Example 5 81 Example 6 79

[0062] As shown in Table 1, the adhesion failure time of the coating material prepared in Example 1 after immersion was significantly longer than that of Comparative Example 1, and the effect of Example 2 was significantly better than that of Comparative Example 2, indicating that the caffeic acid-lupeol-modified silicone oil can effectively improve the adhesion of the coating material to the substrate surface. Furthermore, the effect of Example 5 was significantly better than that of Example 1, and that of Example 6 was significantly better than that of Example 2, indicating that the presence of luteolin-5-O-glucoside and the modified silicone oil have a synergistic effect.

[0063] Test Example 2:

[0064] Coating surface anticoagulation performance test

[0065] Four routine coagulation tests are commonly used to assess a patient's hemostatic function. These tests include prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), and fibrinogen (FIB). By observing the effect of a coating material on these four normal plasma coagulation parameters, the material's anticoagulant ability can be determined.

[0066] Fresh whole blood was collected and centrifuged at 3000 rpm for 10 minutes to obtain platelet-poor plasma for determination of the activated partial thromboplastin time (APTT). The coated sheet was cut into fragments with a surface area of ​​approximately 0.5 x 0.5 cm and placed in a 24-well cell culture plate. An appropriate amount of plasma was added to each well and incubated at 37°C for 1 hour. The incubated plasma was aspirated with a micropipette and added to a microcentrifuge tube. The activated partial thromboplastin time was measured again, and the difference in clotting time was compared.

[0067] The above test was performed on the coating materials obtained in Comparative Examples 1-2 and Examples 1-6. The results are shown in Table 2:

[0068] Table 2 Anticoagulant performance test results

[0069] sample APTT Blank control group 35.42±3.12 Comparative Example 1 36.47±2.17 Comparative Example 2 45.33±3.75 Example 1 35.87±4.13 Example 2 56.74±3.52 Example 3 54.19±2.43 Example 4 55.28±4.11 Example 5 36.43±2.76 Example 6 76.27±4.01

[0070] As shown in Table 2, compared to the blank control, the APTT of the coating material prepared in Comparative Example 1 did not significantly increase, while that in Comparative Example 2 did significantly increase, which is the result of the action of fucoidan sulfate. The effect of Example 1 was comparable to that of Comparative Example 1, while that of Example 2 was significantly better than that of Comparative Example 2, indicating that the combination of caffeic acid-lupeol-modified silicone oil and fucoidan sulfate can effectively enhance the anticoagulant properties of the coating material. Furthermore, the effect of Example 6 was significantly better than that of Example 2, indicating that the presence of luteolin-5-O-glucoside combined with fucoidan sulfate can significantly enhance the anticoagulant effect of the coating material.

[0071] Test Example 3:

[0072] Pain test

[0073] The maximum puncture force of the coatings prepared in Comparative Examples 1 to 2 and Examples 1 to 6 of the present invention applied to needles of different specifications was tested according to GB 15811-2016 for disposable sterile injection needles. The results are shown in the following table:

[0074] Table 3 Puncture force test results

[0075]

[0076]

[0077] As can be seen from Table 3, the puncture force of the coated needle prepared in Example 1 is significantly lower than that of Comparative Example 1, and the puncture force of Example 2 is significantly lower than that of Comparative Example 2, indicating that the use of caffeic acid-lupeol modified silicone oil can effectively improve the lubricity of the coating material. The lower the puncture force, the less pain the patient feels, and the pain of injection is significantly reduced.

[0078] Test Example 4:

[0079] Anti-icing performance test

[0080] The coated sample was mounted on a cooling table. A hollow cylindrical mold with a base diameter of 10 mm and a height of 15 mm was placed above the sample. The cooling table was cooled to -10°C. 1 mL of supercooled water was added to the mold and the temperature was further lowered to -20°C for 1 hour to ensure that the water in the mold was completely frozen. A force gauge (NK-200, JYW GROUP CO., LTD) was used to slowly push the bottom of the mold horizontally until it lifted off the sample surface. The maximum force at the time of release was recorded.

[0081] The above test was performed on the materials obtained in Comparative Examples 1-2 and Examples 1-6. The results are shown in Table 4:

[0082] Table 4 Anti-icing performance test results

[0083] sample Ice adhesion (kPa) Comparative Example 1 110.3 Comparative Example 2 108.4 Example 1 63.4 Example 2 56.7 Example 3 60.3 Example 4 62.7 Example 5 61.5 Example 6 54.9

[0084] As can be seen from Table 4, after the coating material prepared in Example 1 has been frozen, the adhesion of ice on the coating surface is significantly lower than that of Comparative Example 1, and that of Example 2 is lower than that of Comparative Example 2, indicating that the use of caffeic acid-lupeol modified silicone oil can effectively improve the anti-icing performance of the coating material.

[0085] The conventional techniques in the above embodiments are prior arts known to those skilled in the art, and thus will not be described in detail here.

[0086] The above description is merely a specific embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any modifications or substitutions that can be easily conceived by a person skilled in the art within the technical scope disclosed in the present invention should be included in the scope of protection of the present invention. Therefore, the scope of protection of the present invention should be based on the scope of protection of the claims.

Claims

1. A coating material for an injection needle, wherein the coating is formed on the surface of the injection needle by impregnating the needle tip with a coating solution containing a silicone oil modified with caffeic acid and lupeol; The preparation method of the modified silicone oil is specifically as follows: Caffeic acid lupeol and polymethylhydrogen siloxane were dissolved in DMSO, heated to 80-90°C under nitrogen protection, and 3-6 ppm of Speier catalyst was added and reacted for 4-6 hours. The mixture was filtered while hot, cooled to room temperature, rotary evaporated, dried, and then separated and purified by column chromatography to obtain modified silicone oil. The mass ratio of caffeic acid lupeol to polymethylhydrogensiloxane is 3-5:1; The raw material components of the coating solution also include fucoidan sulfate and / or luteolin-5-O-glucoside.

2. The injection needle coating material according to claim 1, characterized in that: The caffeic acid lupeol is used to enhance the lubricity and anti-icing performance of silicone oil.

3. The injection needle coating material according to claim 1, characterized in that: The injection needle tip is immersed in the coating solution and then heated and dried at a temperature less than 150°C.

4. Use of the coating material according to any one of claims 1 to 3 in the surface treatment of a peripheral blood collection needle.

5. The use according to claim 4, characterized in that: The coating thickness is 10-30 μm.

Images